Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 19, 2024
Idarubicin and cytarabine with and without midostaurin for FLT3-mutated acute myeloid leukemia.
Journal: Leukemia & lymphoma
Published: July 07, 2024
Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia.
Journal: Leukemia research
Published: November 21, 2023
Highlights into historical and current immune interventions for cancer.
Journal: International immunopharmacology
Published: December 30, 2022
Role of myeloid-derived suppressor cells in tumor recurrence.
Journal: Cancer metastasis reviews
Published: September 10, 2022
Enrichment of innate immune cells from PBMC followed by triple cytokine activation for adoptive immunotherapy.
Journal: International immunopharmacology
Published: September 08, 2022
Split dose ATG strategy prevents grade III-IV acute GVHD and is associated with immune surrogates of GVL.
Journal: Bone marrow transplantation
Published: May 11, 2022
The Missing LNK: Evolution from Cytosis to Chronic Myelomonocytic Leukemia in a Patient with Multiple Sclerosis and Germline SH2B3 Mutation.
Journal: Case reports in genetics
Published: October 27, 2021
Integrating geriatric assessment and genetic profiling to personalize therapy selection in older adults with acute myeloid leukemia.
Journal: Journal of geriatric oncology
Published: June 06, 2021
Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer.
Journal: Journal for immunotherapy of cancer
Published: May 08, 2021
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy.
Journal: Transplantation and cellular therapy
Published: April 11, 2021
Last Updated: 09/26/2026